- Home
- DOCU vs RVPHW Comparison
DOCU vs RVPHW Comparison
Compare DOCU & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCU
- RVPHW
- Stock Information
- Founded
- DOCU 2003
- RVPHW 2018
- Country
- DOCU United States
- RVPHW United States
- Employees
- DOCU N/A
- RVPHW N/A
- Industry
- DOCU EDP Services
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- DOCU Technology
- RVPHW Health Care
- Exchange
- DOCU Nasdaq
- RVPHW Nasdaq
- Market Cap
- DOCU N/A
- RVPHW N/A
- IPO Year
- DOCU 2018
- RVPHW N/A
- Fundamental
- Price
- DOCU $83.96
- RVPHW $0.12
- Analyst Decision
- DOCU Hold
- RVPHW
- Analyst Count
- DOCU 16
- RVPHW 0
- Target Price
- DOCU $89.38
- RVPHW N/A
- AVG Volume (30 Days)
- DOCU 2.0M
- RVPHW 22.4K
- Earning Date
- DOCU 03-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- DOCU N/A
- RVPHW N/A
- EPS Growth
- DOCU 1852.18
- RVPHW N/A
- EPS
- DOCU 4.82
- RVPHW N/A
- Revenue
- DOCU $2,912,873,000.00
- RVPHW N/A
- Revenue This Year
- DOCU $9.38
- RVPHW N/A
- Revenue Next Year
- DOCU $6.42
- RVPHW N/A
- P/E Ratio
- DOCU $17.43
- RVPHW N/A
- Revenue Growth
- DOCU 7.52
- RVPHW N/A
- 52 Week Low
- DOCU $48.70
- RVPHW $0.13
- 52 Week High
- DOCU $107.86
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- DOCU 31.31
- RVPHW N/A
- Support Level
- DOCU $85.32
- RVPHW N/A
- Resistance Level
- DOCU $89.45
- RVPHW N/A
- Average True Range (ATR)
- DOCU 3.18
- RVPHW 0.00
- MACD
- DOCU -1.00
- RVPHW 0.00
- Stochastic Oscillator
- DOCU 3.52
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.